Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.

about

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

P2860

Q58560605-EB5B010E-1668-4CEA-811D-69E03AD1C345

P2860

Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.

Item

http://www.wikidata.org/entity/Q38901317

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Economic burden of relapsed or ...... s from an international trial.

@en

type

Item

label

Economic burden of relapsed or ...... s from an international trial.

@en

prefLabel

Economic burden of relapsed or ...... s from an international trial.

@en

P1476

Economic burden of relapsed or ...... s from an international trial.

@en

P2093

Abhishek Chitnis

http://www.w3.org/2001/XMLSchema#string

Annette Lam

http://www.w3.org/2001/XMLSchema#string

Britte Kranenburg

http://www.w3.org/2001/XMLSchema#string

Don Robinson

http://www.w3.org/2001/XMLSchema#string

Jianming He

http://www.w3.org/2001/XMLSchema#string

Michael Stokes

http://www.w3.org/2001/XMLSchema#string

Samuel Huse

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical characteristics of patients with relapsed multiple myeloma

Review of health-related quality of life data in multiple myeloma patients treated with novel agents.

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data

Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

When to use the odds ratio or the relative risk?

Self-report of healthcare utilization among community-dwelling older persons: a prospective cohort study

Self-reported utilization of health care services: improving measurement and accuracy.

Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.

Personal financial effects of multiple myeloma and its treatment.

P304

119-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12876

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert Z Orlowski

P577

2017-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28306169

http://www.w3.org/2001/XMLSchema#string

Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.

about

P2860

P2860

Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698